Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XT-0528 in advanced solid tumors
NCT05474859Phase 1Not yet recruiting
- Sponsor
- Xenthera
- Start
- Dec 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of arn-6039 in solid tumor (advanced stage) and metastatic solid tumor (5 cohorts), sponsored by Xenthera. Primary endpoints: Recommended Phase 2 Dose (Th17 suppression) and Recommended Phase 2 Dose (Safety). Planned start Dec 2024; status: not yet recruiting.
02
Drugs
arn-6039
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT05474859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05474859.